Recombinant Human Siglec-11 Fc Chimera Protein, CF

When Recombinant Human Siglec‑11 Fc Chimera (Catalog # 3258-SL) is immobilized at 2 µg/mL (100 µL/well), it binds Biotinylated Recombinant Human Siglec‑15 Fc Chimera Avi-tag protein with an ED50 of 0.7-4.2 μg/mL.

• Reactivity: Hu
• Applications: Binding Activity
• Format: Carrier-Free

Recombinant Human Siglec-11 Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human Siglec‑11 Fc Chimera is immobilized at 2 µg/mL (100 µL/well), it binds Biotinylated Recombinant Human Siglec‑15 Fc Chimera Avi-tag protein with an ED₅₀ of 0.7-4.2 μg/mL.
• Source: Chinese Hamster Ovary cell line, CHO-derived human Siglec-11 protein
  

  Human Siglec-11 Asn17-His543 (Glu84Ala & Lys145Gln) Accession # AAK72907	IEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: AAK72907
• N-terminal Sequence: Asn17
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Gene: SIGLEC11
• Purity: >90%, by SDS-PAGE under reducing conditions and visualized by silver stain.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Binding Activity
• Theoretical MW: 84.4 kDa (monomer).
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 110-135 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >90%, by SDS-PAGE under reducing conditions and visualized by silver stain.
• Reconstitution Instructions: Reconstitute at 100 μg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human Siglec-11 Fc Chimera Protein, CF

• sialic acid binding Ig-like lectin 11
• sialic acid-binding Ig-like lectin 11
• Sialic acid-binding lectin 11
• Siglec11
• Siglec-11

Background

Siglecs (sialic acid binding Ig-like lectins) are I-type lectins that belong to the immunoglobulin superfamily. They are characterized by anN-terminal Ig-like V-set domain which mediates sialic acid binding, followed by a varying numbers of Ig-like C2-set domains. Siglecs-3 and 5 - 13 constitute the CD33/Siglec-3 related group, which are defined by their sequence homology and differential expression in the hematopoietic system (1-3). Mature human Siglec-11 consists of a 534 amino acid (aa) extracellular domain (ECD), a 23 aa transmembrane segment, and a 114 aa cytoplasmic domain. The ECD contains one Ig-like V-set domain, and three Ig-like C2-set domains. The cytoplasmic domain contains two immunoreceptor tyrosine-based inhibitory motifs (ITIMs) (4). A splice variant of Siglec-11 has a deletion of nearly 100 aa in the extracellular juxtamembrane region. Among siglecs, the ECD of Siglec-11 is most closely related to that of Siglec-10 (82% aa sequence identity). The cytoplasmic domains of these proteins are only 20% identical. Siglec-11 is closely related to the pseudogenes Siglec-14 and Siglec-16 (4, 5). Human Siglec-11 shares 90%-96% aa sequence identity with Siglec-11 from great apes. Rodent orthologs of Siglec-11 have not been identified. In human, Siglec-11 is expressed in tissue macrophages, brain microglia, and inflammatory site monocytes (4). Strong microglial expression is specific to humans, as it is less prominent or absent in chimpanzees and orangutans (5). Siglec-11 forms 180 kDa disulfide-linked dimers. It shows a strong binding preference for sialic acid in alpha 2-8 linkage which is unusual for siglecs (4). A conserved arginine in the Ig-like V-set domain only partially contributes to Siglec-11 ligand recognition, in contrast to its being required in other siglecs (4). Tyrosine phosphorylation of the cytoplasmic region of Siglec-11 promotes association with the phosphatases SHP-1 and SHP-2 (4).

1. Varki, A. and T. Angata (2006) Glycobiology 16:1R.
2. Crocker, P.R. (2005) Curr. Opin. Pharmacol. 5:431.
3. Crocker, P.R. (2002) Curr. Opin. Struct. Biol. 12:609.
4. Angata, T. et al. (2002) J. Biol. Chem. 277:24466.
5. Hayakawa, T. et al. (2005) Science 309:1693.

Publications for Siglec-11 (3258-SL)(2)

Publications using 3258-SL

• J Terävä, L Tiainen, U Lamminmäki, PL Kellokumpu, K Pettersson, K Gidwani Lectin nanoparticle assays for detecting breast cancer-associated glycovariants of cancer antigen 15-3 (CA15-3) in human plasma PLoS ONE, 2019-07-25;14(7):e0219480. 2019-07-25 [PMID: 31344060] (Bioassay, Human)
• Chen , Guo-Yun, Brown , Nicholas, Wu , Wei, Khedri , Zahra, Yu , Hai, Chen , Xi, van de Vlekkert , Diantha, D'Azzo , Alessand, Zheng , Pan, Liu , Yang Broad and direct interaction between TLR and Siglec families of pattern recognition receptors and its regulation by Neu1. Elife, 2014-09-03;3(0):e04066. 2014-09-03 [PMID: 25187624] (Bioassay, Human)

Bioinformatics

• Gene Symbol: SIGLEC11
• Uniprot:
  • AAK72907()